Topics

Sobi to buy Dova Pharmaceuticals in £915m deal

06:06 EDT 1 Oct 2019 | Pharmaceutical Business Review

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals

The post Sobi to buy Dova Pharmaceuticals in £915m deal appeared first on Pharmaceutical Business review.

Original Article: Sobi to buy Dova Pharmaceuticals in £915m deal

NEXT ARTICLE

More From BioPortfolio on "Sobi to buy Dova Pharmaceuticals in £915m deal"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...